



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

SODIUM PHENYLBUTYRATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SODIUM PHENYLBUTYRATE	BUPHENYL, PHEBURANE, OLPRUVA, SODIUM PHENYLBUTYRATE	11317		GPI-14 (3090806000)	ROUTE = ORAL

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) and meet **ALL** of the following criteria?
 - There is documentation (e.g., chart notes, lab results, diagnostic test results, etc.) of confirmation of UCD via enzymatic, biochemical or genetic testing
 - The requested medication will be used as adjunctive therapy along with dietary protein restriction
 - The patient cannot be managed by dietary protein restriction or amino acid supplementation alone

If yes, continue to #2.

If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Is the request for Buphenyl (sodium phenylbutyrate)?

If yes, **approve the requested formulation for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Buphenyl tablets: #40 per day.**
- **Buphenyl powder: #25 grams per day.**

If no, continue to #3.

3. Is the request for Pheburane, and the patient meets **ALL** of the following criteria?
 - The patient had a trial of or contraindication to generic sodium phenylbutyrate powder
 - The patient is unable to swallow Buphenyl (sodium phenylbutyrate) tablet

If yes, **approve Pheburane for 12 months by GPID or GPI-14 with a quantity limit of #20 grams per day.**

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

SODIUM PHENYL BUTYRATE

INITIAL CRITERIA (CONTINUED)

4. Is the request for Olpruva, and the patient meets **ALL** of the following criteria?
- The patient had a trial of or contraindication to generic sodium phenylbutyrate powder
 - The patient is unable to swallow Buphenyl (sodium phenylbutyrate) tablet

If yes, **approve the requested strength of Olpruva for 12 months by GPID or GPI-14 as follows:**

- **2 grams: #12 per day.**
- **3 grams: #12 per day.**
- **4 grams: #15 per day.**
- **5 grams: #12 per day.**
- **6 grams: #9 per day.**
- **6.67 grams: #9 per day.**

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SODIUM PHENYL BUTYRATE (Buphenyl, Pheburane, Olpruva)** requires the following rule(s) be met for approval:

- A. You have a urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
- B. There is documentation (such as chart notes, lab results, diagnostic test results) confirming you have a urea cycle disorder via enzymatic, biochemical or genetic testing (types of lab tests)
- C. The requested medication will be used as adjunctive (add-on) therapy along with dietary protein restriction
- D. Your condition cannot be managed by dietary protein restriction or amino acid supplementation alone
- E. **If your request is for Pheburane or Olpruva, approval also requires:**
 1. You have tried or have a contraindication (harmful for) to generic sodium phenylbutyrate powder
 2. You are unable to swallow Buphenyl (sodium phenylbutyrate) tablet

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

SODIUM PHENYLBUTYRATE

RENEWAL CRITERIA

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) **AND** meet the following criterion?
 - The patient has experienced a clinical benefit from baseline (e.g., normal fasting glutamine, low-normal fasting ammonia levels, mental status clarity)

If yes, continue to #2.

If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Is the request for Buphenyl or Pheburane?

If yes, **approve the requested medication for 12 months by GPID or GPI-14 as follows:**

- **Buphenyl tablet: #40 per day.**
- **Buphenyl powder: #25 grams per day.**
- **Pheburane: #20 grams per day.**

If no, continue to #3.

3. Is the request for Olpruva?

If yes, **approve the requested strength of Olpruva for 12 months by GPID or GPI-14 as follows:**

- **2 grams: #12 per day.**
- **3 grams: #12 per day.**
- **4 grams: #15 per day.**
- **5 grams: #12 per day.**
- **6 grams: #9 per day.**
- **6.67 grams: #9 per day.**

If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

SODIUM PHENYLBUTYRATE

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SODIUM PHENYLBUTYRATE (Buphenyl, Pheburane, Olpruva)** requires the following rule(s) be met for renewal:

- A. You have a urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
- B. You have experienced a clinical benefit from baseline (for example you have normal fasting glutamine levels, low-normal fasting ammonia levels, mental status clarity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Buphenyl, Olpruva, or Pheburane.

REFERENCES

- Buphenyl [Prescribing Information]. Deerfield, IL: Horizon Therapeutics USA, Inc.; April 2023.
- Olpruva [Prescribing Information]. Newton, MA: Acer Therapeutics Inc.; December 2022.
- Pheburane [Prescribing Information]. Bryn Mawr, PA: Medunik USA, Inc.; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/01/23

Created: 08/19

Client Approval: 06/23

P&T Approval: 07/23